GlaxoSmithKline plc and Royal Dutch Shell plc: 2 income champions to protect you from Brexit risks

GlaxoSmithKline plc (LON: GSK) and Royal Dutch Shell Plc (LON: RDSB) are two companies that could be immune to Brexit risks.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s one concern dominating the minds of investors at the moment and that’s Brexit. Indeed, if Britain votes to leave the EU on 23 June, the country will be subject to a multi-year period of uncertainty, and it’s this uncertainty that will cause investors the most pain.

To protect against uncertainty and any adverse effects that may come as a result of Britain’s decision to leave the EU, investors could look to large international firms with well-covered dividend yields and well-positioned to succeed in any economic environment.

Defensive business 

GlaxoSmithKline (LSE: GSK) is one such company. The pharmaceuticals giant is a world leader in the production of consumer pharmaceutical products, such as over-the-counter medicines, toothpaste and painkillers. What’s more, the group has a large vaccines division as well as a stake in ViiV Healthcare, a joint venture dedicated to delivering advances in treatment and care for people living with HIV. It’s extremely unlikely that any one of these businesses will see a sudden drop-off in demand for their products in the event of a Brexit.

Moreover, this year Glaxo is on track to report its first year of earnings growth since 2011, so there’s already a significant amount of positive sentiment surrounding the group. City analysts expect the company to report earnings growth of 16% this year, followed by growth of 5% for 2017.

Management has already come out to confirm it’s on track to meet this target. In fact, the first quarter of 2016 was one of the most impressive in several years for the company. Sales increased by 11%, to £6.2bn and earnings per share, excluding exceptional items and adjusted for currency, rose 8% to 19.8p. Shares in Glaxo currently trade at a forward P/E of 15.9 and support a dividend yield of 5.7%.

Global oil company 

Royal Dutch Shell (LSE: RDSB) is another large international company that’s unlikely to be significantly affected by a leave vote. As one of the largest oil traders in Europe and one of the biggest integrated oil companies in the world, Shell is a vital part of the global economy. 

This means that the group is likely to continue to churn out returns for investors no matter what the future holds for the UK economy.

Over the next few years, Shell’s earnings should climb steadily higher as the company continues its integration of recently acquired BG Group and cuts costs further to deal with the slump in oil prices. Asset sales should bolster the enlarged group’s balance sheet while improving margins as low-return assets are sold off.

Shares in Shell currently trade at a forward P/E of 23.7 and support a dividend yield of 7.2%. Management has announced its commitment to the dividend for the foreseeable future so a payout should be secure no matter what the outcome on 23 June.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline and Royal Dutch Shell B. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Royal Dutch Shell B. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

2 huge investment risks I’m worried about in 2025

Ken Hall looks at two big investment risks that are keeping him up at night as we enter 2025 with…

Read more »

Investing Articles

If a 30-year-old put £100 a month in a Stocks and Shares ISA, here’s what they could retire on

Nothing saved for retirement? Don't panic. Our writer explains how regularly investing via a Stocks and Shares ISA could generate…

Read more »

Growth Shares

The IAG share price is at the highest level since the pandemic crash. Here’s what could happen next

Jon Smith explains why the IAG share price has doubled in value over the past year and provides reasons why…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Are we staring at a once-in-a-decade opportunity to get rich from FTSE 350 shares?

While FTSE shares have disappointed lately, Harvey Jones isn't worried. He sees this as a buying opportunity rather than a…

Read more »

Investing Articles

After plunging 65%, is this forgotten FTSE blue-chip the best share for me to buy today?

Harvey Jones is looking for the best share to buy for his Stocks and Shares ISA in 2025 and thinks…

Read more »

Investing Articles

How much do I need to invest in dividend stocks to earn a £1,000 monthly passive income?

Stephen Wright thinks he could turn £15,000 today into £1,000 per month by using one of his favourite dividend stocks…

Read more »

Investing Articles

Down 16% in 2024, will the BP share price bounce back in 2025?

Andrew Mackie assesses why BP remains the laggard among the oil supermajors, and the prospects for its share price this…

Read more »

Investing Articles

As NATO eyes a spending surge in Trump’s second term, is it time for me to buy this FTSE defence technology gem?

This FTSE firm is at the cutting edge of defence technology so looks perfectly placed to benefit from big, planned…

Read more »